Nuveen Asset Management LLC Buys New Stake in Septerna, Inc. (NASDAQ:SEPN)

Nuveen Asset Management LLC bought a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 23,961 shares of the company's stock, valued at approximately $549,000. Nuveen Asset Management LLC owned about 0.05% of Septerna as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Septerna during the fourth quarter valued at $278,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Septerna during the fourth quarter valued at approximately $241,000. Janus Henderson Group PLC acquired a new stake in Septerna during the fourth quarter valued at approximately $25,111,000. Deutsche Bank AG acquired a new stake in Septerna during the fourth quarter valued at approximately $239,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Septerna in the 4th quarter worth approximately $19,736,000.

Septerna Trading Up 5.5%

Shares of NASDAQ SEPN opened at $10.52 on Friday. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The firm's 50-day moving average price is $7.39 and its 200-day moving average price is $12.93.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter. On average, analysts predict that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on SEPN. Wells Fargo & Company boosted their price objective on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Cantor Fitzgerald upped their target price on shares of Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

Want to see what other hedge funds are holding SEPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.